Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Diagnosis
987 results:

  • 1. [First-line Treatment with Furmonertinib Mesylate in lung Adenocarcinoma Patient 
with egfr Exon 20 Insertion Mutantion].
    Li Z; Wei T; Zeng D; Zhao L; Zhang J; Chen L
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):241-244. PubMed ID: 38590198
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
    Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
    Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Assessing egfr-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.
    Chen WC; Cheng WC; Chen CL; Liao WC; Chen CH; Chen HJ; Tu CY; Lin CC; Hsia TC
    Cancer Med; 2024 Apr; 13(7):e7152. PubMed ID: 38549499
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genomic testing and targeted therapy of non-small cell lung cancer in China: a nationwide survey of physicians and clinical pathologists.
    Wang J; Ying J; Wang Z; Meng X; Wu M; Qian C
    Ann Palliat Med; 2024 Mar; 13(2):221-229. PubMed ID: 38509647
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-small cell lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
    Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
    JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Label-free fluorescent sensor for sensitive detection of ctDNA based on water stabilized CsPbBr
    Yang X; Zhao L; Yang S; Tang M; Fa H; Huo D; Hou C; Yang M
    Biosens Bioelectron; 2024 Jun; 253():116165. PubMed ID: 38437747
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Next-Generation Sequencing in lung cancers-A Single-Center Experience in Taiwan.
    Lai WA; Huang YS; Chang KC; Yang SF; Yang CJ; Liu YW; Chen HD
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399524
    [No Abstract]    [Full Text] [Related]  

  • 8. Correlation of MRI quantitative perfusion parameters with egfr, VEGF and egfr gene mutations in non-small cell cancer.
    Zou M; Zhang B; Shi L; Mao H; Huang Y; Zhao Z
    Sci Rep; 2024 Feb; 14(1):4447. PubMed ID: 38396128
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
    Repici A; Ardizzone A; De Luca F; Colarossi L; Prestifilippo A; Pizzino G; Paterniti I; Esposito E; Capra AP
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391974
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with egfr mutation: A case report.
    Imai T; Yoshida T; Ohe Y
    Thorac Cancer; 2024 Mar; 15(9):749-751. PubMed ID: 38379439
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Genomic characteristics and immune landscape of super multiple primary lung cancer.
    Yang Z; Zhou B; Guo W; Peng Y; Tian H; Xu J; Wang S; Chen X; Hu B; Liu C; Wang Z; Li C; Gao S; He J
    EBioMedicine; 2024 Mar; 101():105019. PubMed ID: 38364701
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. 2021 WHO Classification of lung cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
    Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
    Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced egfr-mutated lung adenocarcinoma: A case report.
    Zhang S; Chen L; Zhu K; Meng R
    Indian J Pathol Microbiol; 2024; 67(1):217-222. PubMed ID: 38358227
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Molecular analysis of endobronchial ultrasound needle aspirates in patients with non-small cell lung cancer: Results from the SCOPE database.
    Vakil E; Dumoulin E; Stollery D; Gillson AM; MacEachern P; Dhaliwal I; Mitchell M; Li P; Schieman C; Romatowski N; Chee AC; Tyan CC; Fortin M; Hergott CA; Tremblay A
    Cytopathology; 2024 May; 35(3):378-382. PubMed ID: 38349229
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Nanoplasmonic Detection of egfr Mutations Based on Extracellular Vesicle-Derived egfr-Drug Interaction.
    Han J; Jung JH; Lee SY; Park JH
    ACS Appl Mater Interfaces; 2024 Feb; 16(7):8266-8274. PubMed ID: 38335730
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Epidemiology and Outcomes of Non-small cell lung cancer in South Korea.
    Jung HA; Lee DH; Lim SM; Yu H; Yoon S; Kim D; Kim KP; Jeong H; Doh H; Lim S; Kim J; Zhao X; Horsburgh D; Patel D; Kim JA; Toh KC
    JAMA Netw Open; 2024 Feb; 7(2):e2355331. PubMed ID: 38334998
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation,
    Yang M; Yu P; He Z; Deng J
    Front Immunol; 2023; 14():1266304. PubMed ID: 38332908
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.
    Grafham GK; Craddock KJ; Huang WY; Louie AV; Zhang L; Hwang DM; Parmar A
    Cancer Med; 2024 Feb; 13(3):e6886. PubMed ID: 38317584
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Genomic heterogeneity at baseline is associated with T790M resistance mutations in egfr-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
    Menzel M; Kirchner M; Kluck K; Ball M; Beck S; Allgäuer M; Assmann C; Schnorbach J; Volckmar AL; Tay TKY; Goldschmid H; Tan DS; Thomas M; Kazdal D; Budczies J; Stenzinger A; Christopoulos P
    J Pathol Clin Res; 2024 Mar; 10(2):e354. PubMed ID: 38284983
    [TBL] [Abstract] [Full Text] [Related]  


    of 50.